Meiragtx Holdings plc, of London, was granted a manufacturer's authorization for investigational medicinal products from the U.K.'s Medicines and Healthcare Products Regulatory Agency. The license allows the firm to manufacture gene therapy product candidates in its current GMP-compliant facility.